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PURPOSE: This proof of concept study was designed to assess the influence of prescription-
strength Ibuprofen (IBU) on the repeated bout effect (RBE) of heavy exercise. METHODS: Eight 
males (23 ± 4 yrs) with no recent history of lower-body resistance training completed two 
separate testing phases separated by a seven-day washout period. Each phase consisted of two 
sessions of single-legged resistance exercise (RE), performed on the same leg, separated by ten 
days. One RE trial included 10 sets of 10 repetitions of maximal unilateral eccentric leg 
extensions at 120% 1RM. Each phase was characterized by a distinct treatment of either 800mg 
IBU or placebo (PLA), which subjects consumed 45 minutes prior to RE and in 8h increments for 
72h. A randomly counterbalanced, crossover design was utilized so each subject received both 
treatments. Muscle recovery variables (soreness, muscle function, plasma creatine kinase) were 
measured 24 and 72 hours following each RE session. Magnitude-based inferences were used to 
evaluate all outcomes. RESULTS: The increase in ascending and descending muscle soreness 
24h after the second session of RE (RE2) was ‘likely’ less with PLA compared to IBU. 
Specifically, the reduction in ascending muscle soreness with PLA (RE1: 43mm to RE2: 27mm) 
was absent with IBU (RE1: 39mm to RE2: 39mm). A similar response was observed for 
descending muscle soreness. Furthermore, the impairment in total work performed 72h after RE2 
was ‘likely’ attenuated with PLA (RE1: 598J to RE2: 13.1J), but not IBU (RE1: 335.1J to RE2: 
343J). Decreases in work performed in the first five reps followed a similar pattern. Finally, the 
impact of IBU on all muscle strength and CK measurements were ‘unclear’. CONCLUSIONS: In 
general, IBU consumption appeared to interfere with the RBE, compared to PLA. Follow-up 
work is needed to confirm these findings but these preliminary data suggest that prescription-








The earliest documented use of an analgesic substance was willow bark dating 
back to approximately 300 B.C. (Hersh, 2000). The value of willow bark was originally 
discovered by Hippocrates and used in Europe throughout the Middle Ages to manage 
pain associated with childbirth, wounds, ulcers, and inflammation (Hersh, 2000). The 
analgesic effect of willow bark had been attributed to Salicylic acid, which was later 
isolated and used to create the first non-steroidal anti-inflammatory drug (NSAID), 
aspirin. Produced in bulk by Friedrich Bayer and Company, aspirin became available to 
the public in 1899 (Hersh, 2000). NSAIDs currently account for approximately 30 billion 
annual drug purchases worldwide (Elnachef, 2008) and are primarily used to treat fever, 
inflammation, and pain.  
NSAIDs deliver their effects by impairing cyclooxygenase (COX) enzyme 
activity. NSAIDs prevent COX enzymes from converting arachadonic acid to 
prostaglandins (PG).  There are two major COX isoforms expressed in human tissue. 
COX-1 is found in most tissues and produces PG that control renal function, platelet 
aggregation, and gastric mucosa maintenance (Green, 2001; Hata, 2004). Whereas the 
COX-2 isoform is expressed in response to cellular damage and produces PG that 
regulate inflammatory events. These isoforms are either selectively blocked or 
simultaneously blocked (non-selective), depending on the NSAID. For instance, Aspirin 





NSAID’s are extensively used among athletes, especially during acute periods of 
heavy and/or unaccustomed exercise. Heavy resistance exercise is associated with 
inflammation, joint stiffness, muscle soreness, and impaired muscle function. Likewise, 
muscle damage biomarkers such as creatine kinase (CK) (Peake, 2005; Willoughby, 
2003; Bruunsgaard, 1997; Newham 1986; Paulsen, 2010), Interleukin-6 (IL-6) (Peake, 
2005; Willoughby, 2003; MacIntyre, 2001), and myoglobin (Peake, 2005) are also 
typically elevated following heavy exercise. Although contemporary research may 
suggest otherwise (Peterson, 2003; Donnelly, 1990; Krentz, 2008), NSAID use is 
commonly believed to offset these symptoms. 
Not only do COX-1 and COX-2 have regulatory roles in the aforestated 
physiology, but they also influence processes involved in cellular adaptations to chronic 
exercise. Specifically, PGE2 and PGF2a, manufactured by both COX enzymes, are 
involved heavily in muscle satellite cell proliferation and differentiation, and protein 
turnover (Brewer, 2012). PGF2a stimulates protein synthesis whereas PGE2 stimulates 
protein degradation, collectively leading to a faster rate of protein turnover (Rodemann, 
1982).  There is good evidence that NSAIDs inhibit satellite cell proliferation 
(Mikkelson, 2009; Mackey 2007), protein synthesis (Trappe, 2002; Burd 2010) and PG 
synthesis (Markwork, 2014; Trappe, 2001) after acute exercise. Thus, NSAID’s taken 
proximal to heavy exercise to reduce inflammation and pain may interfere with recovery 
and chronic adaptations. The negative influence of NSAID’s on muscle regeneration and 
adaptation has been shown with animal studies (LaPointe, 2002; Soltow, 2006; Shen, 
2006). Few similar studies have been performed in humans. Surprisingly, two separate 




minimal effect or actually amplifies muscle growth in response to chronic resistance 
training (Krentz, 2008, Trappe, 2011). The authors speculated that a parallel pathway 
may have supercompensated for the COX suppression thereby leading to superior growth 
(Trappe, 2011).  
Little is known about how NSAID use effects non-hypertrophic adaptations, 
particularly with short-term administration that is similar to what is practiced by athletes. 
One such adaptation is the repeated bout effect (RBE), where a single session of 
‘disruptive’ exercise leads to muscle adaptations that safeguard against similar successive 
bouts of exercise-induced muscle damage. Repeated exercise is associated with 
progressively less muscle damage and inflammation (Nosaka, 2001; Eston 1996; Byrnes 
2004; Paulsen 2010). For example, evidence of reduced muscle damage (lower serum 
CK, delayed-onset muscle soreness (DOMS), and myoglobin) has been observed 
following a second session of downhill running when a previous downhill run (Byrnes, 
1985) or isokinetic exercise had been performed (Paulsen, 2010; Eston, 1996). 
Interestingly, these prophylactic adaptations can last up to 6 months in duration (Nosaka, 
2001). The mechanisms responsible for prophylactic adaptations remain unclear but 
likely include motor unit recruitment strategies, cytoskeletal adaptations and the addition 
of sarcomeres (McHugh, 2003). These muscle-specific adaptations likely alter protein 
turnover (Trappe, 2001), satellite cell activity (Mackey, 2007), and inflammation 
(Lapointe, 2002), all processes that are inhibited by NSAID supplementation. Therefore, 
it stands to reason that NSAID supplementation may interfere with muscle remodeling 




To our knowledge, only one study has examined the influence of NSAIDs on 
RBE in humans, and the authors reported null findings (Paulsen, 2010). However, 
subjects consumed Celebrex, a selective COX-2 inhibitor that has minimal effect on 
COX-1. COX-1 works in conjunction with COX-2 as a partial mediator of exercise-
induced protein synthesis (Burd, 2010). Furthermore, COX-2 is likely responsible for 
post-exercise PG production (Trappe, 2011). As a result of its non-selective nature, IBU 
has a low-risk profile and seems to have the most impact in the early stages of post-
exercise recovery on PG synthesis (Markworth, 2014), PGF2a concentrations (Peterson, 
2003; Trappe, 2001) and protein synthesis (Trappe, 2002; Peterson, 2003).  It is logical to 
speculate that IBU may interfere with some of the adaptive characteristics of the RBE, 
however this thesis has not been examined. Therefore, the primary aim is to investigate 
the effects of IBU supplementation on the RBE elicited by consecutive sessions of 













Aims and Hypotheses 
Aim 1: To determine if IBU consumption before and after an initial session of eccentric 
resistance exercise influences skeletal muscle function following a second bout of 
eccentric resistance exercise, compared to placebo (PLA).  
Hypothesis 1: IBU consumption before and after an initial session of eccentric resistance 
exercise will result in greater peak torque decrements following a second session of 
eccentric resistance exercise, compared to PLA. 
 
 Aim 2: To determine if IBU consumption before and after an initial session of eccentric 
resistance exercise influences muscle damage (plasma creatine kinase and muscle 
soreness) following a second session of eccentric resistance exercise, compared to PLA.  
Hypothesis 2: IBU consumption before and after an initial session of eccentric resistance 
exercise will result in more muscle damage following a second session of eccentric 












The prevalence of NSAID use combined with preliminary evidence of impaired muscle 
regeneration and protein turnover during post-exercise recovery points to the value of 
more research on this topic. Coupling unaccustomed resistance exercise with an anti-
inflammatory dose of IBU should create an environment conducive for COX enzyme 
inhibition of inflammation, satellite cell proliferation and fusion, and protein turnover, 
thereby maximizing the potential effect that NSAID’s may have on the RBE. Given the 
non-selective nature of IBU, and the partially shared role of both COX-1 and COX-2 
isoforms in muscle adaptation, this study will provide insight into the potential for 
NSAID treatment to impact skeletal muscle physiology. The findings from this study 
may help fitness professionals, recreational exercisers, and athletes make better informed 
decisions by weighing short term benefits with possible long term detriments when it 

















Eight healthy, active males between the ages of 19 and 32 were recruited from 
James Madison University. To be included, subjects must not have regularly engaged in 
lower body resistance exercise (RE) (> 1 session a week within 3 months of study 
participation). Additionally, subjects must not have consumed any form of NSAID within 
seven days prior to study participation. Study procedures were approved by the James 
Madison University Institutional Review Board. Before participation, and after 
comprehensive verbal and written explanations of the study procedures, all subjects 
provided written consent. Subject characteristics are presented in Table 1.  
 
Experimental Design 
Subjects completed two separate testing phases separated by a washout period of 
at least 7 days. Each testing phase consisted of two single-leg RE sessions, performed on 
the same leg, separated by ten days (Figure 1). Each phase was characterized by 
treatment with either IBU or PLA. A randomly counterbalanced, crossover design was 
utilized so that each subject received both treatments. For example, subjects ingesting 
IBU for the first session of RE with Leg A ingested a PLA pill, matched for size and 
color, for the third session of RE with Leg B, following a 7 day washout period. Prior to 
any testing, subjects that met the inclusion criteria completed a VO2max test and four RE 





One Repetition Maximum Test (1RM) 
Immediately prior to each resistance exercise session, 1RM was tested to 
determine the workload used in the unilateral eccentric leg extensions. Subjects warmed 
up on a treadmill at a self-selected pace for 5 minutes. They then performed a warm-up of 
10 repetitions of unilateral leg extensions at 20% body weight on a standard leg extension 
device (Cybex V3 Series, Medway MA, USA). Immediately after, there was 4 minutes of 
passive recovery followed by two repetitions at 50%-70% of perceived 1 RM. After an 
additional 4 minutes of passive recovery, subjects attempted their 1 RM and continued to 
rest in 4-minute segments between attempts until failure.  
Resistance Exercise (RE) 
 The unilateral resistance exercise protocol was adapted from Burd et al. 
Following 1RM testing, subjects performed 10 sets of 10 repetitions of unilateral 
eccentric leg extensions with a 60 second rest in between sets. The weight was manually 
lifted to 180 degrees and lowered to 90 degrees in a 3 second eccentric phase at 120% of 
the subject’s concentric 1-repetition maximum. If the weight was lowered in less than 0.5 
seconds, the subject completed that set and the following sets were adjusted in 5 pound 
increments so they were able to complete the full protocol. 
 
Washout (WO) 
A washout (WO) phase of at least 7 days followed the second session of RE for 
Leg A. During the WO phase, subjects refrained from any ingestion of NSAIDs, and any 
resistance type exercise. Upon completion of the WO phase, subjects participated in 






Non-Steroidal Anti-Inflammatory Drug (NSAID) Treatment 
Treatments were administered prior to RE and for 72h following RE. Subjects 
received either a PLA pill (lactose) or the anti-inflammatory dose of IBU (2400 mg), split 
into 800mg doses, taken three times a day. The first dose was taken approximately 45 
minutes prior to the initial bout of resistance exercise and in subsequent 8h time 
increments for the next 72 hours. The timing of ingestion immediately after exercise was 
recorded and standardized between phases. To verify drug compliance, subjects sent a 
text confirming the ingestion of their assigned treatment.  
 
MEASUREMENTS 
Cardiorespiratory Fitness (VO2max Test) 
Subjects performed a VO2max test to determine maximal oxygen uptake 7 days 
prior to the first experimental trial. Subjects rode a computerized cycle ergometer 
(Velotron, Racermate Inc, Seattle WA) at a self-selected workload estimated as “a 
comfortable, but not easy pace for a 1-hour ride”.  Workload was increased by 25 W 
every minute until subjects voluntarily requested to stop due to fatigue or are unable to 
continue at a cadence >50 rpm.  Oxygen uptake was assessed during each stage in 30-s 




intervals using indirect calorimetry via an automated Moxus Modular Metabolic System 
(AEI Technologies, Bostrop TX). During the test, heart rate and rate of perceived 
exertion (RPE) was also recorded. 
Skeletal Muscle Function (SMF) 
Peak isokinetic concentric muscle force and work performance was assessed 
following a standardized 5-min warm-up on a treadmill. Skeletal muscle function was 
assessed six times during each testing phase: Pre-RE 1, RE 1+24h, RE 1+72h, Pre-RE 2, 
RE 2+24h, RE 2+72h (Figure 1). Subjects were seated and positioned upright in the 
dynamometer chair with knees bent at a 90-degree angle so the axis of the dynamometer 
was aligned with the axis of rotation of the knee joint. Adjusting straps were secured 
across the subject’s chest, once the chair settings were properly set, to prevent excess 
movement associated with each effort. Peak isokinetic concentric torque was assessed by 
having subjects push as hard as possible against a shin pad connected to an electronic 
dynamometer that controls the speed of movement through the leg-extension. Subjects 
performed 2 sets at 30 degrees per second and 2 sets at 120 degrees per second. Each set 
consisted of 4 repetitions with the first 2 repetitions acting as a warm-up and the last two 
as maximal efforts. Peak isokinetic eccentric torque was assessed by subjects resisting as 
hard as possible against the shin pad connected to the electronically controlled 
dynamometer. The protocol outlined to test peak isokinetic concentric torque was also 
used to test peak isokinetic eccentric torque. All sets were separated by 60 seconds of 
rest. Lastly, subjects performed 30 maximum effort leg-extensions at a controlled speed 





Muscle Soreness  
 Soreness ratings were obtained the day of the damaging trial, and 24h and 72h 
following each bout of RE. A 100mm visual analog scale, with 0 indicating no muscle 
soreness and 100 indicating impaired movement due to muscle soreness was used. 
Subjects completed the scale immediately following ascending, and descending a flight 
of stairs at normal walking speed. 
Venous Blood Draw and Biomarkers 
 Fasting venous blood samples were obtained from an antecubital vein prior to the 
start of each RE trial, 24 hours and 72 hours post RE. Upon entering the lab, subjects 
rested in a blood draw chair for 5 minutes prior to receiving the blood draw. 
Approximately 10mL of whole blood was obtained at each blood draw, and centrifuged 
at 3000 rpm for 20 minutes to remove the plasma portion of the blood. Plasma was stored 
in an -80
o
C freezer for later analysis. Plasma samples were analyzed for muscle 
membrane disruption [creatine kinase (CK)].  CK was subsequently analyzed using an 
automated table-top analyzer (Chemwell-T, Awareness Tech. Inc., Palm City, FL). 
 
DIETARY AND EXERCISE CONTROLS 
Prior to the initiation of testing, subjects were provided with portion sizing guides 
and instructed on how to accurately record dietary intake. Subjects maintained a diet 
record for 4 days, beginning 24 hours prior to the initial RE trial. Subjects submitted their 
initial diet records the morning of their first 72h follow-up trial (from the previous 4 
days). Subjects refrained from alcohol and caffeine 24 hour and 12 hours prior to the start 




selected” meal no less than 12 hours prior to the start of RE trials and follow-up visits. 
Subjects were provided with a standardized meal consisting of a 6-oz yogurt, small box 
of cereal, and orange juice following each RE trial. Subjects consumed the meal within 
60 minutes of the RE trial completion and abstained from any further food or beverage 
intake for the 4 hours following the completion of all RE trials.  
Subjects refrained from heavy physical activity 72 hours pre and post RE trial. To 
ensure compliance, subjects completed a 72h physical activity log prior to each RE trial. 
Subjects did not engage in any heavy exercise in the previous 24h before each RE trial. In 
order to avoid any unintended prophylactic adaptions, subjects had not performed any 
resistance type of exercise within the previous 3 months.  
 
STATISTICAL ANALYSES 
Magnitude-based inferences about the data were derived using methods described 
by Hopkins and colleagues (31). A standardized difference in means (mean difference 
between treatments divided by the between-subject SD under PLA conditions: SD units) 
was calculated for each variable whereby observed values equivalent to or exceeding 0.2 
SD units was quantified as a substantial treatment effect (i.e. threshold for substantial 
effect) (31). The 0.2 SD unit threshold was used for all variables. 
A published spreadsheet (33) was used to determine the likelihoods of the true 
treatment effect (of the population) reaching the substantial change threshold (0.2 SD); 
these were classified as <1% almost certainly no chance, 1-5% = very unlikely, 5-25% = 
unlikely, 25-75% = possible, 75-95% = likely, 95-99% = very likely, and >99% = almost 




<25% and the effect was clear, it is classified as a ‘trivial’ effect. If 90% confidence 
intervals included values that exceeded the substantial change threshold for both a 
positive and negative effect, effects were classified as ‘unclear’ (>5% chance of reaching 
the substantial threshold for both a positive and negative effect). For ease of 
interpretation data are displayed as raw means ± SD and/or percent difference between 


















































PURPOSE: This proof of concept study was designed to assess the influence of prescription-
strength Ibuprofen (IBU) on the repeated bout effect (RBE) of heavy exercise. METHODS: Eight 
males (23 ± 4 yrs) with no recent history of lower-body resistance training completed two 
separate testing phases separated by a seven-day washout period. Each phase consisted of two 
sessions of single-legged resistance exercise (RE), performed on the same leg, separated by ten 
days. One RE trial included 10 sets of 10 repetitions of maximal unilateral eccentric leg 
extensions at 120% 1RM. Each phase was characterized by a distinct treatment of either 800mg 
IBU or placebo (PLA), which subjects consumed 45 minutes prior to RE and in 8h increments for 
72h. A randomly counterbalanced, crossover design was utilized so each subject received both 
treatments. Muscle recovery variables (soreness, muscle function, plasma creatine kinase) were 
measured 24 and 72 hours following each RE session. Magnitude-based inferences were used to 
evaluate all outcomes. RESULTS: The increase in ascending and descending muscle soreness 
24h after the second session of RE (RE2) was ‘likely’ less with PLA compared to IBU. 
Specifically, the reduction in ascending muscle soreness with PLA (RE1: 43mm to RE2: 27mm) 
was absent with IBU (RE1: 39mm to RE2: 39mm). A similar response was observed for 
descending muscle soreness. Furthermore, the impairment in total work performed 72h after RE2 
was ‘likely’ attenuated with PLA (RE1: 598J to RE2: 13J), but not IBU (RE1: 335J to RE2: 343J). 
Decreases in work performed in the first five reps followed a similar pattern. Finally, the impact 
of IBU on all muscle strength and CK measurements were ‘unclear’. CONCLUSIONS: In 
general, IBU consumption appeared to interfere with the RBE, compared to PLA. Follow-up 
work is needed to confirm these findings but these preliminary data suggest that prescription-







NSAIDs (Non-Steroidal Anti-inflammatory Drugs) currently account for 
approximately 30 billion annual drug purchases worldwide (Elnachef, 2008) and are 
primarily used to treat fever, inflammation, and pain. NSAIDs deliver their effects by 
impairing cyclooxygenase (COX) enzyme activity. NSAIDs prevent COX enzymes from 
converting arachadonic acid to prostaglandins (PG).  There are two major COX isoforms 
expressed in human tissue. COX-1 is found in most tissues and produces PG that control 
renal function, platelet aggregation, and gastric mucosa maintenance (Green, 2001; Hata, 
2004). The COX-2 isoform is expressed in response to cellular damage and produces PG 
that regulate inflammatory events. These isoforms are either selectively blocked or 
simultaneously blocked (non-selective), depending on the NSAID. 
Heavy resistance exercise is associated with inflammation, joint stiffness, muscle 
soreness, and impaired muscle function. Likewise, muscle damage biomarkers such as 
creatine kinase (CK) (Peake, 2005; Willoughby, 2003; Bruunsgaard, 1997; Newham 
1986; Paulsen, 2009), Interleukin-6 (IL-6) (Peake, 2005; Willoughby, 2003; MacIntyre, 
2001), and myoglobin (Peake, 2005) are also typically elevated following heavy exercise. 
As such, NSAIDs are extensively used among athletes in an attempt to manage acute 
periods of heavy and/or unaccustomed exercise. 
Not only do COX-1 and COX-2 have regulatory roles in the aforestated 
physiology, but they also influence processes involved in cellular adaptations to chronic 
exercise. Specifically, PGE2 and PGF2a, manufactured by both COX enzymes, are 




turnover (Brewer, 2012). Thus, NSAIDs taken proximal to heavy exercise to reduce 
inflammation and pain may interfere with recovery and chronic adaptations.  
Little is known about how NSAID use effects skeletal muscle adaptations, 
particularly with short-term administration. One such adaptation is the repeated bout 
effect (RBE), where a single session of ‘disruptive’ exercise leads to muscle adaptations 
that safeguard following similar successive bouts of exercise. Repeated exercise is 
associated with progressively less muscle damage and inflammation (Nosaka, 2001; 
Eston 1996; Byrnes 2004; Paulsen 2010). Interestingly, these prophylactic adaptations 
can last up to 6 months in duration (Nosaka, 2001). These muscle-specific adaptations 
likely alter protein turnover, satellite cell activity, and inflammation, all processes that are 
inhibited by NSAID supplementation. 
To our knowledge, only one study has examined the influence of NSAIDs on 
RBE in humans, and the authors reported null findings (Paulsen, 2010). However, 
subjects consumed Celebrex, a selective COX-2 inhibitor. COX-1 works in conjunction 
with COX-2 as a partial mediator of exercise-induced protein synthesis (Burd, 2010). 
Furthermore, COX-2 is likely responsible for post-exercise prostaglandin production 
(Trappe, 2012). IBU has a low-risk profile and seems to impact several key processes 
during the early stages of post-exercise recovery including PG synthesis (Markworth, 
2014), PGF2a concentrations (Peterson, 2003; Trappe, 2001) and protein synthesis 
(Trappe, 2002; Peterson, 2003). Therefore, the primary aim of this study is to investigate 
the effects of IBU supplementation on the RBE elicited by consecutive sessions of 





MATERIALS AND METHOD 
Subjects 
Eight healthy, active males between the ages of 19 and 32 were recruited from 
James Madison University. To be included, subjects must not have regularly engaged in 
lower body resistance exercise (RE) (> 1 session a week within 3 months of study 
participation). Additionally, subjects must not have consumed any form of NSAID within 
seven days prior to study participation. Study procedures were approved by the James 
Madison University Institutional Review Board. Before participation, and after 
comprehensive verbal and written explanations of the study procedures, all subjects 
provided written consent. Subject characteristics are presented in Table 1.  
 
Experimental Design 
Subjects completed two separate testing phases separated by a washout period of 
at least 7 days. Each testing phase consisted of two single-leg RE sessions, performed on 
the same leg, separated by ten days (Figure 1). Each phase was characterized by a distinct 
treatment of either IBU or PLA. A randomly counterbalanced, crossover design was 
utilized so that each subject received both treatments. For example, subjects ingesting 
IBU for the first session of RE with Leg A ingested a PLA pill, matched for size and 
color, for the third session of RE with Leg B, following a 7 day washout period. Prior to 
any testing, subjects that met the inclusion criteria completed a VO2max test and four RE 






One Repetition Maximum Test (1RM) 
Immediately prior to each resistance exercise session, 1RM was tested to 
determine the workload used in the unilateral eccentric leg extensions. Subjects warmed 
up on a treadmill at a self-selected pace for 5 minutes. They then performed a warm-up of 
10 repetitions of unilateral leg extensions at 20% body weight on a standard leg extension 
device (Cybex V3 Series, Medway MA, USA). Immediately after, there was 4 minutes of 
passive recovery followed by two repetitions at 50%-70% of perceived 1 RM. After an 
additional 4 minutes of passive recovery, subjects attempted their 1 RM and continued to 
rest in 4-minute segments between attempts until failure.  
Resistance Exercise (RE) 
 The unilateral resistance exercise protocol was adapted from Burd et al. 
Following 1RM testing, subjects performed 10 sets of 10 repetitions of unilateral 
eccentric leg extensions with a 60 second rest in between sets. The weight was manually 
lifted to 180 degrees and lowered to 90 degrees in a 3 second eccentric phase at 120% of 
the subject’s concentric 1-repetition maximum. If the weight was lowered in less than 0.5 
seconds, the subject completed that set and the following sets were adjusted in 5 pound 
increments so they were able to complete the full protocol. 
 
Washout (WO) 
A washout (WO) phase of at least 7 days followed the second session of RE for 
Leg A. During the WO phase, subjects refrained from any ingestion of NSAIDs, and any 
resistance type exercise. Upon completion of the WO phase, subjects participated in 






Non-Steroidal Anti-Inflammatory Drug (NSAID) Treatment 
Treatments were administered prior to RE and for 72h following RE. Subjects 
received either a PLA pill (maltodextrin) or the anti-inflammatory dose of IBU (2400 
mg), split into 800mg doses, taken three times a day. The first dose was taken 
approximately 45 minutes prior to the initial bout of resistance exercise and in subsequent 
8h time increments for the next 72 hours. The timing of ingestion immediately after 
exercise was recorded and standardized between phases. To verify drug compliance, 
subjects sent a text confirming the ingestion of their assigned treatment.  
 
MEASUREMENTS 
Cardiorespiratory Fitness (VO2max Test) 
Subjects performed a VO2max test to determine maximal oxygen uptake 7 days 
prior to the first experimental trial. Subjects rode a computerized cycle ergometer 
(Velotron, Racermate Inc, Seattle WA) at a self-selected workload estimated as “a 
comfortable, but not easy pace for a 1-hour ride”.  Workload was increased by 25 W 
every minute until subjects voluntarily requested to stop due to fatigue or are unable to 
continue at a cadence >50 rpm.  Oxygen uptake was assessed during each stage in 30-s 




intervals using indirect calorimetry via an automated Moxus Modular Metabolic System 
(AEI Technologies, Bostrop TX). During the test, heart rate and rate of perceived 
exertion (RPE) was also recorded. 
Skeletal Muscle Function (SMF) 
Peak isokinetic concentric muscle force and work performance was assessed 
following a standardized 5-min warm-up on a treadmill. Skeletal muscle function was 
assessed six times during each testing phase: Pre-RE 1, RE 1+24h, RE 1+72h, Pre-RE 2, 
RE 2+24h, RE 2+72h (Figure 1). Subjects were seated and positioned upright in the 
dynamometer chair with knees bent at a 90-degree angle so the axis of the dynamometer 
was aligned with the axis of rotation of the knee joint. Adjusting straps were secured 
across the subject’s chest, once the chair settings were properly set, to prevent excess 
movement associated with each effort. Peak isokinetic concentric torque was assessed by 
having subjects push as hard as possible against a shin pad connected to an electronic 
dynamometer that controls the speed of movement through the leg-extension. Subjects 
performed 2 sets at 30 degrees per second and 2 sets at 120 degrees per second. Each set 
consisted of 4 repetitions with the first 2 repetitions acting as a warm-up and the last two 
as maximal efforts. Peak isokinetic eccentric torque was assessed by subjects resisting as 
hard as possible against the shin pad connected to the electronically controlled 
dynamometer. The protocol outlined to test peak isokinetic concentric torque was also 
used to test peak isokinetic eccentric torque. All sets were separated by 60 seconds of 
rest. Lastly, subjects performed 30 maximum effort leg-extensions at a controlled speed 





Muscle Soreness  
 Soreness ratings were obtained the day of the damaging trial and 24h and 72h 
following each bout of RE. A 100mm visual analog scale, with 0 indicating no muscle 
soreness and 100 indicating impaired movement due to muscle soreness was used. 
Subjects completed the scale immediately following ascending, and descending a flight 
of stairs at normal walking speed. 
 
Venous Blood Draw and Biomarkers 
 Fasting venous blood samples were obtained from an antecubital vein prior to the 
start of each RE trial, 24 hours and 72 hours post RE. Upon entering the lab, subjects 
rested in a blood draw chair for 5 minutes prior to receiving the blood draw. 
Approximately 10mL of whole blood was obtained at each blood draw, and centrifuged 
at 3000 rpm for 20 minutes to remove the plasma portion of the blood. Plasma was stored 
in an -80
o
C freezer for later analysis. Plasma samples were analyzed for muscle 
membrane disruption [creatine kinase (CK)].  CK was subsequently analyzed using an 
automated table-top analyzer (Chemwell-T, Awareness Tech. Inc., Palm City, FL). 
 
DIETARY AND EXERCISE CONTROLS 
Prior to the initiation of testing, subjects were provided with portion sizing guides 
and instructed on how to accurately record dietary intake. Subjects maintained a diet 
record for 4 days, beginning 24 hours prior to the initial RE trial. Subjects submitted their 
initial diet records the morning of their first 72h follow-up trial (from the previous 4 




of RE trials and follow-up visits respectively. Subjects consumed their final “self-
selected” meal no less than 12 hours prior to the start of RE trials and follow-up visits. 
Subjects were provided with a standardized meal consisting of a 6-oz yogurt, small box 
of cereal, and orange juice following each RE trial. Subjects consumed the meal within 
60 minutes of the RE trial completion and abstained from any further food or beverage 
intake for the 4 hours following the completion of all RE trials.  
Subjects refrained from heavy physical activity 72 hours pre and post RE trial. To 
ensure compliance, subjects completed a 72h physical activity log prior to each RE trial. 
Subjects did not engage in any heavy exercise in the previous 24h before each RE trial. In 
order to avoid any unintended prophylactic adaptions, subjects had not performed any 
resistance type of exercise within the previous 3 months.  
 
STATISTICAL ANALYSES 
Magnitude-based inferences about the data were derived using methods described 
by Hopkins and colleagues (31). A standardized difference in means (mean difference 
between treatments divided by the between-subject SD under PLA conditions: SD units) 
was calculated for each variable whereby observed values equivalent to or exceeding 0.2 
SD units was quantified as a substantial treatment effect (i.e. threshold for substantial 
effect) (31). The 0.2 SD unit threshold was used for all variables. 
A published spreadsheet (33) was used to determine the likelihoods of the true 
treatment effect (of the population) reaching the substantial change threshold (0.2 SD); 
these were classified as <1% almost certainly no chance, 1-5% = very unlikely, 5-25% = 




certain. If the percent chance of the effect reaching the substantial change threshold was 
<25% and the effect was clear, it is classified as a ‘trivial’ effect. If 90% confidence 
intervals included values that exceeded the substantial change threshold for both a 
positive and negative effect, effects were classified as ‘unclear’ (>5% chance of reaching 
the substantial threshold for both a positive and negative effect). For ease of 
interpretation data are displayed as raw means ± SD and/or percent difference between 






















Soreness values following ascension and descension of one flight of stairs 24h 
after RE are displayed in Figure 1. Data in parenthesis represents the difference between 
the two repeated RE trials for each treatment. RE1 indicates the 1
st
 initial bout of 
damaging exercise while RE2 indicates the 2
nd




There was a ‘likely’ treatment effect on the RBE for ascending soreness at the 24-
hr mark. With PLA, the increase in ascending soreness following RE1 (43mm) was ‘very 
likely’ greater than the increase in soreness 24 hrs following RE2 (27mm). Conversely, 
there were no clear changes in soreness 24 hrs after RE1 (39mm) versus RE2 (39mm) 
with IBU.  
There were no clear treatment differences in soreness at the 72-hr time point. 
Ascending soreness following RE1 (40mm) was ‘likely’ greater than RE2 (15mm) with 
PLA. The IBU treatment showed a similar response with soreness ‘likely’ greater after 
RE1 (30mm) compared to RE2 (21mm). 
 
Descending stairs 
There was a ‘likely’ treatment effect on the RBE for descending soreness at the 
24-hr mark. With PLA, the increase in descending soreness following RE1 (55mm) was 




Conversely, there were no clear changes in soreness 24 hrs after RE1 (48mm) versus RE2 
(42mm) with IBU.  
There were no clear treatment differences in soreness at the 72-hr time point. 
Descending soreness following RE1 (47mm) was ‘very likely’ greater than RE2 (20mm) 
with PLA. The IBU treatment showed a similar response with soreness ‘likely’ greater 
after RE1 (35mm) compared to RE2 (21mm). 
 
Whole Muscle Function 
Peak muscle torque values are displayed in Table 2. 
 
Concentric Isokinetic Peak Torque 
There were no clear treatment differences on the RBE at both 24 hrs and 72 hrs 
for isokinetic peak torque at 30 deg·sec
-1
 and 120 deg·sec
-1
. Decrements in torque at 30 
deg·sec
-1
 24 hrs after RE2 (33 Nm) were ‘possibly’ lower compared to RE1 (49 Nm) with 
PLA. However, it was not clear if decreases in torque were less after RE2 (37 Nm) 
compared to RE1 (45 Nm) with IBU. Likewise, declines in torque 72 hrs post RE2 (11 
Nm) were ‘likely’ smaller in comparison to RE1 (41 Nm) with PLA. Similarly, recovery 
after RE2 (23 Nm) compared to RE1 (22 Nm) was not clear with IBU. 
 It was not clear if decreases in torque at 120 deg·sec
-1
 24 hrs after RE1 (33 Nm) 
were regained after RE2 (30 Nm) with PLA. Contrarily, torque decrements ‘likely’ 
diminished after RE2 (23 Nm) compared to RE1 (38 Nm) with IBU. Declines in peak 
torque 72h following RE1 (34 Nm) were ‘likely’ restored after RE2 (8 Nm) with PLA.  
However, it was not clear if decrements in torque recovered after RE2 (12 Nm) compared 




Eccentric Isokinetic Peak Torque 
There were no clear treatments effects on the RBE at both 24 hrs and 72 hrs for 
isokinetic peak torque at 30 deg·sec
-1
 and 120 deg·sec
-1
. Decrements in torque at 30 
deg·sec
-1
 24 hrs following RE1 (44 Nm) were ‘possibly’ lower after RE2 (28 Nm) with 
PLA. It was not clear if the same was seen after RE2 (45 Nm) compared to RE1 (62 Nm) 
with IBU. Likewise, declines in torque 72 hrs after RE2 (-5 Nm) were ‘likely’ smaller in 
comparison to RE1 (25 Nm) with PLA. It was not clear if similar recovery after RE2 (10 
Nm) compared to RE1 (17 Nm) was occurred with IBU. 
 Decreases in torque at 120 deg·sec
-1
 24 hrs after RE1 (60 Nm) were ‘likely’ 
regained after RE2 (22 Nm) with PLA. Comparably, torque decrements ‘likely’ 
diminished after RE2 (38 Nm) compared to RE1 (67 Nm) with IBU. It was not clear if 
restoration of peak torque 72 hrs following RE1 (34 Nm) happened after RE2 (-10 Nm) 
with PLA. Declines in torque were ‘possibly’ reduced after RE2 (3 Nm) compared to RE1 
(17 Nm). 
 
Whole Muscle Performance 
Total work values are displayed in Figure 2 and work done in the first 5 reps is 
displayed in Figure 3.  
 
Work 
There were ‘likely’ treatment effects at both 24 hrs and 72 hrs for total work done 
and work performed within the first five reps (FFR). The impairment in total work 24 hrs 
following RE2 (365 J) was ‘very likely’ less compared to RE1 (1,005 J) with PLA. With 




same pattern was observed at 72 hrs as decreases in work performed ‘likely’ recovered 
from RE1 (598 J) to RE2 (13 J) with PLA. It was not clear if differences existed between 
RE1 (335 J) and RE2 (343 J) with IBU.  
Furthermore, the decrease in FFR 24 hrs following RE1 (307 J) ‘very likely’ 
improved after RE2 (116 J) with PLA. However, it was not clear if FFR was less impaired 
after RE2 (178 J) compared to RE1 (255 J) with IBU. In accordance, the reduction in FFR 
72 hrs following RE1 (206 J) ‘likely’ improved following RE2 (9 J) with PLA. There was 
no clear improvement from RE1 (84 J) to RE2 (73) with IBU.  
 
Creatine Kinase Levels 
CK levels are displayed in Table 3.  
 
Plasma Creatine Kinase (CK) 
There were no clear treatment effects on the RBE at both 24 hr and 72 hr time 
points. The plasma CK response 24 hr following RE2 (90 U/L) was ‘likely’ diminished 
compared to RE1 (144 U/L) with PLA. Similarly, it was ‘likely’ that CK was attenuated 
after RE2 (68 U/L) compared to RE1 (145 U/L) with IBU. CK response 72h after RE1 
(1590 U/L) was ‘very likely’ larger compared to RE2 (11 U/L) with PLA. However, with 










The primary goal of this proof-of-concept investigation was to determine if short-
term IBU consumption interferes with well-documented skeletal muscle prophylactic 
adaptations that occur after an initial bout of heavy unaccustomed exercise, otherwise 
known as the RBE. We quantified the magnitude of the RBE by assessing muscle 
function and perceived soreness after two identical eccentric exercise sessions (unilateral 
leg extension) separated by 10 days. Contralateral legs were exposed to this design, one 
with acute IBU and the other with PLA. The main finding was that IBU appeared to 
impair the RBE, compared to PLA. 
 It is well established that after an initial bout of damaging exercise, any 
subsequent session of similarly heavy exercise is ensued by comparatively less muscle 
soreness (Eston, 1996; Byrnes, 1985) and attenuated impairments in muscle function 
(Eston, 1996). A RBE clearly occurred in the present study at both 24 hrs and 72 hrs 
following damaging exercise in virtually all of the markers during the PLA treatment 
(soreness, 30 deg/sec concentric and eccentric peak torque at 72h, 120 deg/sec concentric 
peak torque at 72h, 120 deg/sec eccentric peak torque at 24h, total work, work performed 
in the first 5 reps and CK). Evidence of a RBE with IBU was less consistent (soreness at 
72h, 120 deg/sec concentric and eccentric peak torque at 24h, and CK at 24h). These 
separate adaptations lead to clear treatment differences in the RBE between IBU and 
PLA, altogether suggesting that IBU inhibits prophylactic adaptations. There is only one 
similar study available for comparison and it contradicts the current data (Paulsen, 2010).  
However, Paulsen used a smaller drug dose (400mg) and a different class of NSAID 




pathways, as COX-1 is thought to be involved in cellular pathways necessary for skeletal 
muscle remodeling such as protein synthesis and satellite cell proliferation. Specifically, 
COX-1 is believed to be involved in the increase in protein synthesis following exercise 
(Burd, 2010) and PG production necessary for early signaling post-exercise recovery 
(Markworth, 2014).  Indeed, IBU has been shown to suppress protein synthesis (Trappe, 
2002) and PGF2a production (Trappe 2001) following exercise, while COX-2 inhibition 
has not (Burd, 2010). Similarly, satellite cell proliferation has also occurred through the 
use of nonselective COX inhibitors similar to IBU (Mackey, 2007; Mikkelson, 2010) but 
not with COX-2 inhibitors (Paulsen, 2010).  Another possible explanation for the 
discrepant findings is that Paulson administered 400mg of Celebrex twice a day 
compared to the 800 mg IBU dose taken thrice a day in the present study. The dosage 
used by Paulsen is not considered anti-inflammatory (Abramson, 1989) and may not be a 
large enough stimulus to cause any disruption in muscle regeneration and function. 
In humans, long-term effects of using non-selective COX inhibitors, Naproxen 
sodium and IBU, have been documented (Krentz, 2008; Brewer, 2015). Although NSAID 
supplementation had negative effects on early adaptations to resistance exercise in the 
more recent study, these impacts diminished over the course of the 6-week resistance 
training program and had no repercussions on morphological adaptations (Brewer, 2015). 
Comparably, IBU did not influence muscle hypertrophy or strength following 6 weeks of 
resistance training in the earlier investigation (Krentz, 2008). Though it is difficult to 
extrapolate the current data, it is possible that the negative impact of IBU on the RBE in 
the first 10 days observed here may dissipate over time.  Though the differences in 




extended duration. In rebuttal, one animal study communicates how non-selective COX 
inhibition may have negative long-term consequences on skeletal muscle. Concerning 
findings were revealed when rabbits were administered Flurbiprofen (non-selective COX 
inhibitor) (Mishra, 2006). Those treated with the NSAID enhanced muscle function more 
so than the controls at days 3 and 7 after one damaging bout of exercise. However, 28 
days later torque deficits increased and force production decreased in the Flurbiprofen 
group (Mishra, 2006). It is worthy to note that while this study did not examine the RBE, 
the associated long-term impairment hints at the possible consequences of using non-
steroidal anti-inflammatory drugs. 
The current research design also allowed us to provide insight into the 
prophylactic efficacy of IBU following acute exercise. The aforementioned dosage of 
2400mg of IBU has only been used one other time to our knowledge (Pizza, 1998). 
Findings indicated prophylactic IBU consumption did not influence peak torque and 
isometric strength after performing one bout of eccentric arm curls (Pizza, 1998). 
Conversely, NSAID use has assisted with an increase in muscle function acutely after 
heavy exercise (Hasson, 1993; Mishra, 2006). This was not the case within the present 
study as it was ‘unclear’ if muscle soreness, CK, peak torque and work performed 
benefited from IBU consumption after the initial bout. These findings are in agreement 
that IBU consumption does not influence muscle soreness (Bourgeois, 1999; Krentz, 
2008; Trappe, 2001) or muscle damage (Bourgeois, 1999).  
The subjects in the current study had a wide range of body masses; 69 to 105 kg, 
potentially adding variability to the outcomes. Although it has yet to be thoroughly 




mass may not elicit the same response as subjects with less body mass. However, a 
previous investigation with individuals of similar mass to the current study found that 
1200mg of IBU elevated serum IBU concentrations and attenuated PG synthesis to a 
similar extent across subjects (Markworth, 2014). Therefore, the current dose was likely 
enough to suppress inflammatory processes in all subjects. Furthermore, the correlation 
between body mass and the affect of IBU on the RBE was 0.045, suggesting that body 
mass had virtually no influence on the results. 
In general, the data indicate that IBU consumption blunted the RBE. This was 
most obvious for muscle soreness and leg extension work. To our knowledge, this is the 
first evidence that acute IBU consumption proximal to initial damaging exercise hinders 
tolerance to the subsequent bout of heavy exercise. We recommend thoughtful 
consideration before consuming IBU as a recovery aid, as it may negatively influence 






















Table 1. Descriptive Characteristics 
 Height (cm) Mass (kg) Age (yrs) VO2max (ml/kg/min) 
N = 8 179.6 ± 7.0 82.1 ± 12.3 22.8 ± 4.1 45.3 ± 7.0 










).   
RE1 RE2 















































































































Data are displayed as mean ± SD * RBE ‘likely’  
* 
* 







Table 3. CK values (U/L) Pre, 24h and 72h post RE. 
Treatment  Pre 24h 72h 
IBU 
RE1 114.8 ± 31.2 259.3 ± 147.8 800.7 ± 1360.3 
RE2 124.7 ± 35.4 192.6 ± 59.10 118.5 ± 28.5 
PLA 
RE1 127.4 ± 66.8 271.8 ± 111.7 1515.8 ± 1992.1 
RE2 143.0 ± 46.6 233.3 ± 84.00 143.5 ± 56.4 





































































Figure 2. Difference in perceived ascending muscle soreness from pre to 24 hrs and 
pre to 72h following RE.  
 
[RE2] values represent muscle soreness assessed 10 days after the first IBU 































Figure 3. Difference in total work performed from pre to 24h and pre to 72h.  
 
 
[RE2] values represent work performed 10 days after the first IBU or 
PLA trial [RE1]. Data are displayed as mean ± SE. *RBE ‘likely’  

























Figure 4. Difference in work performed during the first five reps from pre to 24h and  
to 72h.  
 
[RE2] values represent work performed 10 days after the first IBU or PLA 
trial [RE1]. Data are means ± SE. 
*RBE ‘likely’ 
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Appendix A   
Maximum VO2 Data Table 
Bike 
Date_______________ 
Subject__________   Gender__________    
Age___________   Body Weight (kg)________   
Height (cm)___________  Resting HR_____________   
 
Seat Height:_____________  Handlebar Height:___________ 
Seat Fore/aft:_____________  Handlebar fore/aft:___________ 
  

















Subject #: _________    Date:_____________   
 
Trial:   FAM1  FAM2   Leg Involved:      Left  Right 
 
Explain the protocol in detail to ensure the subject knows what is expected. 
 












Arm attachment position:_________ 
 
 
Speed  Concentric PeakT         Eccentric PeakT  
 
30  __________           __________ 
 
30  __________           __________  
 
120  __________           __________ 
  
120  __________           __________ 
   
 
 
                                                 Fatigability 
 
     Work 1
st
 third                    Work Last third 
  









Muscle Soreness Questionnaire 
 
Subject #       Date:   
 
Trial:   A B C D 
 
Circle:  Pre  24h 72h 
 




Please place a mark on the line below corresponding to your level of muscle soreness 
 
0 millimeters (left) = complete absence of muscular soreness 
100 millimeters (right) = extremely sore with noticeable pain and stiffness at all times 
 
 
Pressure while seated:                                               
         
 
            0 mm                          100 mm 
                          
 
Ascending 1 flight of stairs: 
 
0 mm                            100 mm 
 
Descending 1 flight: 
 






















Subject #: _________   Date:___________   
 
Trial: A  B C D  
 
Circle:  Pre 24h 72h   Leg Involved:    Left  Right 
 
Explain the protocol in detail to ensure the subject knows what is expected. 
 












Arm attachment position:_________ 
 
Speed        Concentric PeakT         Eccentric PeakT  
 
30    __________             __________ 
 
30    __________             __________  
 
120    __________             __________ 
  
120    __________              __________ 
   
Fatigability 
 
     Work 1
st
 third                    Work Last third 
  
       ____________                     ____________ 
 
 










Subject Number:____      Date:____________ 
 
Trial:   A     B      C     D 
 
 
1 repetition maximum protocol: 
 
10 warm up reps at 20% body weight 20% body weight:_______lbs. 
4 minutes of passive recovery 
2 reps at 50-70% of their perceived 1RM 50-70% perceived 1RM:_______lbs. 
4 min of passive recovery  
1RM attempt     First 1RM attempt:_______lbs. 
4 min of passive recovery    Second 1RM attempt:_______lbs. 
Repeat until failure     Third 1RM attempt:_______lbs. 
      Fourth 1RM attempt:________lbs. 
      Fifth 1RM attempt:________lbs. 
      Sixth 1RM attempt:________lbs. 
 
      1RM:______lbs. 





10 sets of 10 repetitions at 120% 1RM 
 
1. Set # when weight was lowered:_____ 
Weight lowered to:_______lbs. 
 
2. Set # when weight was lowered:_____ 
Weight lowered to:_______lbs. 
 
3. Set # when weight was lowered:_____ 
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in conducting the research.  He/she further certifies that he/she has completed 
training regarding human participant research ethics within the last three years. 
_________________________________________ ________________ 
Principal Investigator Signature   Date 
 
_________________________________________ ________________ 
Principal Investigator Signature   Date 
______________________________ ________________ 
Principal Investigator Signature   Date 
_________________________________________ ________________ 
Faculty Advisor Signature    Date 
Submit an electronic version (in a Word document) of your ENTIRE protocol to 
researchintegrity@jmu.edu. 
Provide a SIGNED hard copy of the Research Review Request Form to: 
Office of Research Integrity, MSC 5738, 601 University Boulevard, Blue Ridge Hall, Third 








Purpose and Objectives 
Rationale 
Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used after performing 
unaccustomed exercise, presumably in an attempt to manage the resulting inflammation 
and soreness/stiffness. Mechanistically, NSAIDs elicit their effect by interfering with the 
COX enzyme (COX-1 and/or COX-2) pathway to prevent the conversion of arachadonic 
acid to prostaglandins (3). While COX inhibition may transiently mask the acute 
detrimental consequences of heavy exercise (soreness and inflammation) (4,7), 
manipulation of this pathway also influences cellular processes needed for desirable 
adaptations to repeated exercise. Specifically, various NSAIDs (both COX-2 and COX-
1/COX-2 inhibitors) can blunt post-exercise protein synthesis and satellite cell 
proliferation (5,9). Therefore, it is logical to speculate that NSAID supplementation may 
interfere with select cellular adaptations to heavy exercise.  
The prophylactic effect of exercise is a hallmark adaptation that commences following 
the first session of naïve exercise so that subsequent bouts of identical exercise elicit 
progressively less damage and functional impairment. While one recent study reported 
that short-term COX-2 inhibition (Celebrex) does not interfere with prophylactic 
adaptations (7), there is good reason to believe that simultaneous COX-1 and COX-2 
inhibition (Ibuprofen) is more potent and therefore may be more likely to negatively 
impact prophylactic adaptations. Moreover, previous research on the topic used the 
largest over the counter dose of Ibuprofen (1200 mg/day) despite the fact that it is well 
known that prescription strength Ibuprofen doses (2400 mg/day) not only relieves pain 
but also influences inflammation, which has an important role in tissue remodeling. Thus, 
the aim of the proposed study is to test the hypothesis that acute prescription strength 
Ibuprofen treatment will impair prophylactic adaptations, thereby leading to greater 
muscle damage and impaired recovery following a subsequent session of heavy 
resistance exercise (following drug washout), compared to a placebo treatment.  
Note: All potential subjects will be seen by Dr. Diduch at the James Madison University 
student health center where they will complete the health history questionnaire, screening 
questionnaire (attachments B & E) and be health screened. Low risk subjects (described 
below) will receive a prescription for placebo (800 mg 3 x day for 72 hours – 9 doses), 
and Ibuprofen (800 mg 3 x day for 72 hours) to be filled at the James Madison University 
student health center pharmacy. JMU pharmacist Ron French has agreed to prepare 
bottles of placebo and Ibuprofen and to dispense the bottles to our research subjects. 
Copies of screening materials will be kept on file at the health center and copies will be 






These findings may be used to help fitness professionals, recreational exercisers, and 
athletes make better-informed decisions regarding NSAID supplementation, as they 
weigh short-term benefits against possible long-term consequences.  
Procedures 
Source and Number of Subjects 
8-12 recreationally active male adults will be recruited from James Madison University 
and the surrounding area. The researchers will discuss the study with 
undergraduate/graduate students in Kinesiology, University Sports clubs, and will also 
recruit using word of mouth and social media (i.e. facebook).  Information provided to 
potential subjects will include: basic criteria for inclusion in the study, a brief description 
of the study demands, and benefits of participation (see Attachment A).  Subjects will be 
selected using the inclusion criteria below, based on their responses to questionnaires 
(Attachments B, E). Note that female subjects will not be included. We have a track 
record of incorporating females when feasible. However, it is well known that estrogen 
levels, and therefore menstrual phase, impact muscle recovery, the chief variable in this 
study. So, the cost of additional analyses and design requirements of this particular 
project prevent us from including females.  
Inclusion Criteria 
To be eligible for study participation, each subject must meet the following criteria: 
 Age and Sex: Males: 18-45 years 
 Subjects must not have performed resistance exercise (RE) or been a part of a 
resistance training program within the last 3 months.  
 NSAID use: Subjects will not have consumed NSAID’s within the previous 7 
days.  
 Subjects are willing and able to give written informed consent, and to understand, 
participate and comply with the study requirements 
 Health: Characterized as “low risk” for exercise complications using criteria from 
the American College of Sports Medicine’s Guidelines for Exercise Testing and 
Prescription (9th Ed., ACSM, 2014).  Low risk is characterized by the ACSM as 
individuals “who are asymptomatic and register no more than one risk factor 
threshold” from the list below: 
- Age: Males > 45 yrs 
- Family History: Myocardial infarction, coronary revascularization, or 




relative, or before 65 years of age in mother or other female first-degree 
relative. 
- Cigarette Smoking: Current cigarette smoker or those who quit within the 
previous 6 months. 
- Hypertension: Systolic blood pressure ≥ 140 mmHg or diastolic ≥ 90 
mmHg, confirmed by measurements on at least two separate occasions, or 
on antihypertensive medication. 
- Dyslipidemia: Low-density lipoprotein (LDL) cholesterol > 130 mg/dl or 
high-density lipoprotein (HDL) < 40 mg/dl, or on lipid-lowering 
medication.  If total serum cholesterol is all that is available use > 200 
mg/dl rather than LDL ≥ 130 mg/dl. 
- Impaired fasting glucose: Fasting glucose ≥ 100 mg/dl confirmed by 
measurements on at least two separate occasions 
- Obesity: Body mass index > 30 kg/m2 
- Sedentary lifestyle: Persons not participating in a regular exercise program 
or not meeting the minimal physical activity recommendations from the 
U.S. Surgeon General’s Report 
- High-serum HDL Cholesterol: This is considered a “negative risk factor”, 
so 1 of the above risk factors can be subtracted if HDL > 60 mg/dl 
 
As recommended by the ACSM, we will use the AHA/ACSM Health/Fitness 
Facility Pre-participation Screening Questionnaire to identify the above criteria 
above (ACSM, 2014, p. 25; see Attachment B).  
Study Design 
General Description 
The intent of this design is to determine whether short-term Ibuprofen use during a 
critical window of recovery (72 hours) influences longer-term prophylactic adaptations. 
The proposed project will implement a randomized, double blind, placebo-controlled, 
crossover design whereby subjects will perform unilateral leg-extension resistance 
exercise.  For each subject, one leg will be assigned to Placebo whereas the contralateral 
leg will be assigned Ibuprofen (treatments will be administered for 3 days following the 
initial session of unaccustomed exercise).  For example, approximately 7 days following 
preliminary testing, 6 subjects will perform one-legged resistance exercise and receive 
Placebo capsules whereas 6 subjects will perform one-legged resistance exercise and 
receive Ibuprofen (Leg A – Exercise Session 1). The same leg will undergo identical 
exercise 10 days later, without treatment (Leg A – Exercise Session 2). Recovery will be 
assessed following each session. 10 days following the Leg A – Exercise Session 2, the 
opposite leg will perform one-legged resistance exercise and receive the opposite 




again without treatment (Leg B – Exercise Session 2).  A schematic of the general study 
design is displayed in Figure 1. 
Subjects will receive the treatment in intermittent doses for 72 hours with treatments 
commencing on the morning of the first resistance exercise trial. The same leg will be 
tested again 10 days later allowing for full muscle recovery, for blood markers to return 
to baseline, and for Ibuprofen to ‘wash-out’ so that it does not affect muscle recovery 
following the second session of knee extensions. This will allow us to profile the 
prophylactic effect without the confounding acute impact of Ibuprofen.  
 
Figure 1: Study Design 
 
RE= resistance exercise; Recovery will be assessed at 24 and 72 hrs following each 
RE. 
The study will consist of a total of sixteen (16) laboratory visits totaling approximately 11 
hours of commitment (in addition to completing dietary records). Specifically, subjects 
will report to the laboratory for one pre-testing trial, three familiarization trials, four 
resistance exercise trials, and eight follow-up trials. Detailed information for each of 
these trials is provided below: 
Pre-testing 1 (60 min):  
 Informed Consent – Before testing is initiated, subjects will be given consent 
forms to read and sign that provide a comprehensive description of the study, the 
risks and benefits associated with the study, and the ways in which confidentiality 
will be maintained (see Informed Consent).     
 
 
Leg A Leg B 




 Body Mass and Height - Subjects will have their body weight measured to the 
nearest 0.2 kg, and height measured to the nearest 0.5 cm.  
 
 VO2max - During this assessment, subjects will perform a graded exercise test to 
determine their maximal oxygen uptake (VO2max). Subjects will ride a cycle 
ergometer at a self-selected workload estimated as “a comfortable, but not easy 
pace for a 1-hour ride”.  Workload will be increased by 25 W every 2 minutes 
until subjects voluntarily request to stop due to fatigue or are unable to continue at 
a cadence >50 rpm.  Oxygen uptake will be assessed at each stage during this test. 
VO2max will be assessed directly from data obtained during the test and used as a 
descriptive characteristic. 
 
 Skeletal Muscle Function Familiarization – Peak isokinetic concentric muscle 
force and muscle fatigability will be assessed following the VO2max. This test will 
be conducted using a Biodex muscle function device (Biodex Medical Systems 
Inc., Shirley NY). Muscle function will be assessed by having subjects push as 
hard as possible against a shin pad that is connected to an electronic device that 
controls speed of movement through the leg-extension. 10 continuous leg-
extension repetitions will be performed. Note: Only 10 repetitions will be 
performed to minimize muscle adaptation to practice. Actual testing will include 
30 repetitions. The purpose of this session is to familiarize the subjects with the 
equipment and procedures to minimize learning and improve reliability during the 
experimental trials.  
 
Familiarization Trials (n =3; 15 minutes each):  
 Skeletal Muscle Function - Peak isokinetic concentric muscle force and 
fatigability will be assessed following a standardized treadmill warm-up (3.5 
mph; 5 min). See above for details. When combined with the initial skeletal 
muscle function familiarization test described above, each leg will receive two 
familiarization trials. 
 
Resistance Exercise Trials (n=4; 60 minutes each): 
 Muscle Soreness - Soreness ratings will be obtained using a 100mm visual analog 
scale, with 0 indicating no muscle soreness and 100 indicating impaired 
movement due to muscle soreness. Subjects will also be asked to complete the 
scale immediately following ascending, and descending a flight of stairs at normal 
walking speed.  
 Blood Sample – Following 5 min of seated rest, fasting venous blood samples will 
be obtained from an antecubital vein. Approximately 10 ml of whole blood will 
be obtained at each blood draw, and centrifuged at 7000 rpm to remove the serum 
portion of the blood. Serum will be stored in a   -80
o





 Skeletal Muscle Function - Peak muscle force and fatigability will be assessed 
following a standardized treadmill warm-up (3.5 mph; 5 min). See above for 
details. 
 
 Resistance Exercise (RE) – The RE will consist of 100 unilateral knee extensions 
performed at a fast speed (180 degrees per second) and 100 unilateral knee 
extensions performed at a slow speed (30 degrees per second). The knee 
extensions will be performed in sets of 10 (10 repetitions performed within each 
set) with a 60 second rest in between sets. Subjects will be split into two groups 
and randomly selected to perform the resistance exercise first with either their 
dominant or non-dominant leg.  The RE protocol is in line with previous literature 
(1,2,6). 
 
Follow-Up Visits (n=8; 30 min each): 
 Muscle Soreness - Soreness ratings will be obtained using a 100mm visual analog 
scale, with 0 indicating no muscle soreness and 100 indicating impaired 
movement due to muscle soreness.  
 Blood Sample – Fasting venous blood samples will be obtained from an 
antecubital vein.  
 Skeletal Muscle Function - Peak muscle force and fatigability will be assessed 




As outlined above, for each subject, one leg will be assigned to Placebo whereas the 
opposite leg will be assigned to Ibuprofen.  Subjects will ingest their respective treatment 
capsules with water 3 x daily for 3 d, starting ~45 min prior to the initial RE test (upon 
arrival in the laboratory), and in subsequent 6 hour time increments for the next 72 hours.  
The subjects will send a photo or text to the investigators immediately upon consumption 
of each capsule taken outside of the laboratory as evidence of consumption.  
 Placebo: Maltodextrin-filled capsules (carbohydrate) 
 Ibuprofen: The maximum daily over the counter dosage of Ibuprofen 
(2400mg/day) concealed in capsules matching placebo 
 
Dietary and Exercise Controls   
Subjects will be asked to keep a dietary log (see Attachment C) beginning 24 hours prior 




returning in 72 hours for a follow-up visit, subjects will submit their initial diet records 
and be provided with a copy to use as a template to replicate their diet for the same four 
days surrounding each of the next 3 RE sessions. 
Subjects will consume their final ‘self-selected’ meal no less than 12 hours prior to the 
RE sessions and follow-up visits (i.e. dinner on the evening prior to testing).  Subjects 
will also be provided with a 500 kilocalories of Ensure Active following each RE 
sessions (4 feedings). Subjects will be instructed to consume the feeding 60 min of RE 
trial completion and then to refrain from any food or beverage intake until 4 hours 
following RE trial completion. 
Subjects will also be instructed to abstain from alcohol and caffeine for 24 and 12 hours, 
respectively, prior to each RE trial and follow-up visit.   
Subjects will be instructed to refrain from heavy exercise for 72 hours prior to the RE 
trials as well as the 72 hours following each RE trial.  Subjects will record all physical 
activity performed throughout the duration of the study, beginning with 72 hours prior to 
the initial RE trial (40 d) (see Attachment D). Subjects will also be instructed to abstain 
from the use of any supplements to enhance recovery throughout the duration of the 
study. 
Dependent Measurements 
All dependent measures will be assessed immediately prior to each RE trial and again 24 
hours and 72 hours following each RE trial.  
 Skeletal Muscle Function - Peak isokinetic concentric muscle force and 
fatigability will be assessed with BioDex. See above for details. 
 
 Muscle Soreness - Soreness ratings will be obtained using a 100mm visual analog 
scale will be obtained immediately following ascending, and descending a flight 
of stairs at normal walking speed.  
 Biomarkers – Blood samples will be analyzed for serum biomarkers of 
inflammation [(Interleukin-6 (IL-6) and TNF-alpha (TNF-a)] and muscle 




The risks of blood sampling using venipuncture include possible mild bruising, and the 
risk of transfer of blood-borne pathogens, as well as possible risks of infection or skin 
irritation. These risks are considered to be minimal, and all safety precautions for handing 




will wear latex gloves at all times during blood sampling and testing. A sharps container 
lined with a biohazard bag will be used for all sharp objects involved in the blood 
sampling; all other materials (i.e. gloves, gauze pads, etc.) used during the sampling will 
be put in a separate waste disposal unit lined with a biohazard bag. Both investigators 
who will be involved in blood draws (and handling of blood) have been trained in these 
phlebotomy techniques, and completed JMU blood-borne pathogen training.  The total 
amount of blood obtained during this study is approximately 120 ml. For reference, this 
amount is ~ 1/3 of a can of soda, or 25% of the amount given when donating blood in a 
single session (approximately 1 pint, or 473 ml).  This amount of blood is the minimum 
required to perform the assays for CK, BDNF, IL-6 and TNF-α and to assess the time-
course changes in these variables as a result of the exercise sessions.  Subjects will be 
instructed to refrain from donating blood during the study period. 
Skeletal Muscle Function 
The risks of BioDex muscle function testing include soreness from exertion 24-48 hours 
post and potential lightheadedness or loss of consciousness if correct form is not utilized.  
Participants will be instructed in correct form and breathing techniques prior to testing. 
VO2max test and Resistance Exercise Trials 
According to the American College of Sports Medicine’s Guidelines for Exercise Testing 
and Prescription, the risk associated with heavy exercise for individuals categorized as 
“low risk” is very minimal, and physician supervision is not necessary.  The conditions 
that the exercise sessions are to take place are likely safer than the typical exercise 
environments of the subjects.   Any subjects who do not meet the ACSM criteria for “low 
risk” will not be allowed to participate in the study. In the unlikely event of cardiac or 
other complications during exercise, an emergency plan is in place. This includes 
immediate access to a phone to call emergency personnel. In addition, at least one of the 
listed investigators will be present during the exercise sessions, and both are CPR 
certified.   
The resistance exercise trials will likely evoke a large amount of muscle soreness that 
may persist for up to 7 d following exercise. The amount of soreness is similar to that 
experienced following unaccustomed vigorous physical activity (e.g. descending on a 
hike, playing a game of basketball, football, ultimate Frisbee, etc.) 
Ibuprofen 
The use of Ibuprofen may be associated with an increased risk of gastrointestinal (GI) 
events such as bleeding, ulcers within the stomach, and heart attack. However, serious GI 
reactions and CV risks are extremely low given the 3-day dosing regimen in this study. 




and smoking regularly, are over the age of 60, are on blood thinners or blood pressure 
medication. Other possible side effects include rash, flare of asthma, temporary vision 
changes, dizziness, abdominal pain, upset stomach, burping, bloating, cloudy urine, 
diarrhea, decrease in urine production, constipation, heartburn, indigestion, and shortness 
of breath (8). Another possible risk is drug interaction with other medications such as 
increased bleeding risk if taken with anticoagulants, increased serum lithium levels, 
increased toxicity of methotrexate, or decreased effectiveness of diuretics. The research 
participants will be strongly encouraged to communicate any suspected or observed side 
effects (whether it is listed above or not) of the treatments with one of the investigators or 
Dr. Diduch. 
Benefits 
All participants will gain valuable knowledge about their own muscular physiology and 
information regarding the potential influence of Ibuprofen on adaptations to 
unaccustomed exercise.  Subjects will also receive a free VO2max test (valued at ~$150) 
and subjects that complete all phases of data collection will be entered into 3 random 
drawings for $125. 
Data Analysis 
This study will utilize a counterbalanced, between-subject design to examine the effects 
of Ibuprofen on prophylactic adaptations to exercise, compared to placebo. Dependent 
measurements will be examined with (treatment x time) ANOVAs. It is hypothesized that 
Ibuprofen will interfere with prophylactic adaptations to exercise, thus leading to larger 
amounts of muscle soreness, membrane disruption, and decrements in muscle function 
following the second treadmill session, compared to placebo. Statistical significance will 
be set at p ≤ 0.05 for these analyses.  
Data Handling 
Participation in this research will not be completely anonymous due to the inevitable 
familiarity of the research team with some of the subjects.  However, all subjects will be 
assigned an individual identification number to ensure that the data remains confidential.  
All files will be coded with the identification number. Coding sheets with participants' 
names and corresponding identification numbers along with consent forms will be kept, 
indefinitely, in a locked filing cabinet by Dr. Luden separate from the data files. All hard 
copies of data (coded with ID number) will be stored, indefinitely, separately in locked 
file cabinets in the Human Performance Lab.  Electronic data and files will be stored, 
indefinitely, on a password-protected computer, and will only contain de-identified 
information. Only the identification number will be entered into the computer when 
creating data spreadsheets and therefore subject’s names will not be available to those 





The results from this study may be presented at physiological conferences and in 
professional journals.   Participants will not be identified in reports, and data from 
individual subjects will not be reported in a manner that would render it possible for 
participants to be identified.  Target audiences for these results include, but are not 
limited to, JMU faculty, peer review professional journals, and physiology conference 
participants.  In addition, the final aggregate results of the study will be made available to 
each of the subjects upon request. 
Vulnerable Population 
Data will not be gathered on minors, prisoners, pregnant women, fetusus, neonates, 
cognitively impaired persons, or other protected or potentially vulnerable populations. 
Deception 
No deception will be used. 
Experience of the Researchers 
Nicholas D. Luden, Ph.D. is an Assistant Professor of Exercise Physiology and Interim 
Director of JMU’s Human Performance Laboratory.  He has published >15 peer-
reviewed manuscripts in the field of exercise physiology.   His primary research interests 
revolve around skeletal muscle function and how it can be optimized using training 
and/or nutritional strategies.  He has accumulated a substantial amount of both basic and 
applied laboratory experience over the past decade, the majority of which has been 
gained while conducting research on endurance athletes.   
Jessica G. Ehrbar is a first-year graduate student in Exercise Physiology and a recent 
graduate of our undergraduate Kinesiology program. Over the past couple years, she has 
gained significant research experience through volunteer and practicum hours performed 
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James Madison University 





I, ________________________, hereby agree on _______________ (date) to participate 
in the research project conducted by Dr. Nick Luden and Jessica Ehrbar from James 
Madison University titled “The Effects of Ibuprofen on Prophylactic Adaptations to 
Heavy Exercise” 
 
The primary goal of this study is to examine if Ibuprofen use affects muscle adaptations 




I understand that I will undergo the following testing in the study: 
 
You will be asked to visit the Human Performance Laboratory (Godwin 209) a total of 16 
times and the James Madison University Health Center to see Dr. Diduch for a health 
screening.  Specifically, you will be asked to report to the James Madison University 
Health Center to be health screened prior to participation and to receive a prescription for 
the Ibuprofen and placebo treatments to be filled at the James Madison University Health 
Center Pharmacy (at no cost). Also, you will report to the laboratory for one preliminary 
trial, three familiarization trials, four experimental trials, and eight follow up visits 24 and 
72 hours after the experimental trials. The preliminary tests will require approximately 60 
minutes, familiarization trials will require approximately 15 minutes, experimental trials 
will require approximately 60 minutes, and the eight follow up trials will require 
approximately 30 minutes, for a total time commitment of approximately 11 hours in 
addition to completing dietary and physical activity records.  Detailed information for 




Before any physical evaluation is given, you will be asked to complete screening forms 
and an informed consent, to ensure that you meet the study criteria, that you do not have 
any risk factors for heavy exercise, and that you do not have any known allergies to any 
non-steroidal anti-inflammatory drugs.   In the process of filling out these forms, you will 
be asked to share information regarding your general health and lifestyle with the 
researchers. If you meet the criteria for the study, the researchers will measure your 
height and weight and you will perform a cardiorespiratory fitness test.  During this 
assessment, an exercise test will be conducted to determine your maximal oxygen uptake 
(VO2max).  To do this, you will ride a stationary cycle at an initial workload that is ‘fairly 
easy’.   Workload will be increased by 25 watts every 2 minutes during the test.   You 




unable to continue at a cadence >50 revolutions per minute. After the VO2max test, a test 
measuring muscle function will be performed. This test will be conducted using a Biodex 
muscle function device (Biodex Medical Systems Inc., Shirley NY). Peak unilateral 
isokinetic force (power) and fatigability will be assessed by having you push as hard as 
possible against a shin pad that is connected to an electronic device that controls speed of 
movement through the leg-extension.  You will perform a trial comprised of 10 
continuous leg-extension repetitions. The purpose of this session is to familiarize you 
with the equipment and procedures to minimize learning and improve reliability during 





You will then be asked to return several days following the initial pre-testing to perform 
another Biodex familiarization session. Two additional familiarization Biodex sessions 




Following preliminary/familiarization testing, you will be asked to perform four total 
trials of unilateral knee extensions (two trials for each leg). The two trials performed with 
the same leg will be separated by 10 days and the two sets of trials will be separated by 7 
days.  
 
Resistance Exercise: The RE will consist of 100 one-legged knee extensions performed at 
a fast speed (180 degrees per second) and 100 one-legged knee extensions performed at a 
slow speed (30 degrees per second). The knee extensions will be performed in sets of 10 
(10 repetitions performed within each set) with a 60 second rest in between sets.  
 
Muscle Soreness: You will evaluate your muscle soreness using a visual scale with 0 
indicating (i.e.) no muscle soreness and 100 indicating impaired movement due to muscle 
soreness. This will be done before each of the experimental trials. 
 
Blood Sample: Following 5 minutes of rest, blood samples will be obtained. 
Approximately 10 ml of whole blood will be obtained at each blood draw. This will be 
performed before each RE trial. 
 
Muscle Function Test (Biodex Isokinetic Dynamometer):  Following a 5-minute treadmill 




You will be asked to return to the lab 24 and 72 hours following each resistance exercise 





Muscle Soreness: You will evaluate your muscle soreness using a visual scale with 0 
indicating (i.e.) no muscle soreness and 100 indicating impaired movement due to muscle 
soreness. This will be done before each of the experimental trials. 
 
Blood Sample: Following 5 minutes of rest, blood samples will be obtained. 
Approximately 10 ml of whole blood will be obtained at each blood draw. This will be 
performed before each RE trial. 
 
Muscle Function Test (Biodex Isokinetic Dynamometer):  Following a 5-minute treadmill 





Approximately 45 minutes before entering the lab for the resistance exercise trial, you 
will be required to consume 800mg of either Ibuprofen or Placebo. Every six hours for 
the next 72 hours, 800mg of Ibuprofen will be ingested, for a total of 9 doses of Placebo 
and 9 doses of Ibuprofen over the course of the study. You will be required to send a text 
or picture for verification to the researcher immediately following each dose. 
 
 
Dietary, Exercise, and Medication Controls 
 
You will be asked to complete a diet record for 4 days beginning 24 hours prior to the 
initial treadmill trial.  You will submit your initial diet records the morning of your first 
72 hours follow-up trial (diet records from previous 4 days). A copy of your initial 
dietary records will then be provided, which you will be asked to use as a template when 
replicating your dietary habits during the 4 days around the second treadmill trial (24 
hours prior and 72 hours after).  
 
You will consume a final ‘self-selected’ meal no less than 12 hours prior to the start of 
RE trials and follow-up visits (i.e. dinner on the evening prior to testing).  You will also 
be provided with a 500 kilocalories of Ensure Active following each RE sessions (4 
feedings). You will be instructed to consume the feeding 60 minutes of RE trial 
completion and then to refrain from any food or beverage intake until 4 hours following 
RE trial completion.. 
 
You will also be instructed to abstain from alcohol and caffeine for 24 and 12 hours, 
respectively, prior to each resistance exercise (RE) trial and follow-up visit.   
 
You will be instructed to refrain from heavy exercise for 72 hours prior to the RE trials as 
well as the 72 hours following each RE trial. All physical activity performed throughout 
the duration of the study will be recorded, beginning with 72 hours prior to the initial 
treadmill trial (40 days). You will also be instructed to abstain from the use of any 





You will be instructed to refrain from consumption of other nonsteroidal drugs (e.g. 
ibuprofen, advil, motrin, aleve, naproxen) starting 4 days prior to the initial trial and for 





VO2max test and Resistance Exercise Trials 
You are expected to be honest about disclosing all known risk factors to the researcher. 
According to the American College of Sports Medicine, the risks associated with 
maximal exercise/testing for healthy individuals are very minimal.   If you do not meet 
the criteria for “low risk”, you will not be allowed to participate in the study. In the 
unlikely event of cardiac or other complications during exercise, an emergency plan is in 
place.  This includes immediate access to a phone to call emergency personnel.   In 
addition, each of the investigators is CPR certified.    
 
The resistance exercise will likely evoke a large amount of muscle soreness that may 
persist for up to 7 days following exercise. The amount of soreness is similar to that 
experienced following unaccustomed vigorous physical activity (e.g. descending on a 
hike, playing a game of basketball, football, ultimate Frisbee, etc.) The degree of soreness 




The risks of blood sampling using venipuncture include possible mild bruising, and the 
risk of transfer of blood-borne pathogens, as well as possible risks of infection or skin 
irritation. These risks are considered to be minimal, and all safety precautions for handing 
blood samples will be followed according to OSHA protocols, including: investigators 
will wear latex gloves at all times during blood sampling and testing. A sharps container 
lined with a biohazard bag will be used for all sharp objects involved in the blood 
sampling; all other materials (i.e. gloves, gauze pads, etc.) used during the sampling will 
be put in a separate waste disposal unit lined with a biohazard bag. All trash bags will be 
taken to Rockingham Memorial Hospital for disposal. Both investigators who will be 
involved in blood draws (and handling of blood) have been trained in these phlebotomy 
techniques, and completed JMU blood-borne pathogen training. The total amount of 
blood obtained during this study is approximately 120 ml. For reference, this amount is ~ 
1/3 of a can of soda, or 25% of the amount given when donating blood in a single session 
(approximately 1 pint, or 473 ml). This amount of blood is the minimum required to 
perform the assays for CK, BDNF, IL-6 and TNF-α and to assess the time-course 
changes in these variables as a result of the exercise sessions.  Subjects will be instructed 









Skeletal Muscle Function 
The risks of BioDex muscle function testing include soreness from exertion 24-48 hours 
post and potential lightheadedness or loss of consciousness if correct form is not utilized.  
Participants will be instructed in correct form and breathing techniques prior to testing. 
 
Ibuprofen Use 
The use of Ibuprofen may be associated with an increased risk of gastrointestinal (GI) 
events such as bleeding, ulcers within the stomach, and heart attack. However, serious GI 
reactions and CV risks are extremely low given the 3-day dosing regimen in this study. 
These events are more likely to occur if you have a history of ulcers, partake in drinking 
and smoking regularly, are over the age of 60, are on blood thinners or blood pressure 
medication. Other possible side effects include rash, flare of asthma, temporary vision 
changes, dizziness, abdominal pain, upset stomach, burping, bloating, cloudy urine, 
diarrhea, decrease in urine production, constipation, heartburn, indigestion, and shortness 
of breath (8). Another possible risk is drug interaction with other medications such as 
increased bleeding risk if taken with anticoagulants, increased serum lithium levels, 
increased toxicity of methotrexate, or decreased effectiveness of diuretics. You are 
strongly encouraged to communicate any suspected or observed side effects (whether it is 
listed above or not) of the treatments with one of the investigators or Dr. Diduch.  
 
Benefits 
You will gain valuable knowledge about your own muscular physiology and information 
regarding the potential influence of Ibuprofen on adaptations to unaccustomed exercise.  
You will also receive a free VO2max test (valued at ~$150) and will be entered into 3 
random drawings for $125, if all phases of data collection are completed. 
 
Inquiries 
You may have questions or concerns during the time of your participation in this study, 
or after its completion.  If you have any questions about the study, contact Nicholas D. 
Luden, Ph.D. at ludennd@jmu.edu or by phone at 540-568-4068. 
 
Questions about Your Rights as a Research Subject 
Dr. David Cockley  
Chair, Institutional Review Board 






All data and results will be kept confidential.  You will be assigned an identification 
code.   At no time will your name be identified with your individual data. The researcher 
retains the right to use and publish non-identifiable data.   All data will be kept secured in 




Freedom of Consent 
Your participation is entirely voluntary.   You are free to choose not to participate.   
Should you choose to participate, you can withdraw at any time without consequences of 
any kind. 
 
I have read this consent form and I understand what is being requested of me as a 
participant in this study.   I freely consent to participate.   I have been given satisfactory 
answers to my questions.   The investigator provided me with a copy of this form.   I 
certify that I am at least 18 years of age. 
 
 
   








































AHA/ACSM Health/Fitness Facility Pre-participation Screening Questionnaire 
Assess your health status by marking all true statements 
 
History 
You have had: 
   a heart attack 
   heart surgery 
   cardiac catheterization 
   coronary angioplasty (PTCA) 
   pacemaker/implantable cardiac 
   defibrillator/rhythm disturbance 
   heart valve disease 
   heart failure 
   heart transplantation 
   congenital heart disease 
Symptoms 
   You experience chest discomfort with exertion 
   You experience unreasonable breathlessness 
   You experience dizziness, fainting, or blackouts 
   You take heart medications 
 
Other Health Issues 
   You have diabetes 
   You have asthma or other lung disease 
   You have burning or cramping sensation in your lower  
   legs when walking short distances 
   You have musculoskeletal problems that limit your  
   physical activity 
   You have concerns about the safety of exercise 




Cardiovascular risk factors 
   You are a man older than 45 years 
   You smoke, or quit smoking within the previous 6 mo. 
   Your blood pressure is > 140/90 mmHg 
   You do not know your blood pressure 
   You take blood pressure medication 
   Your blood cholesterol level is > 200 mg/dl 
   You do not know your cholesterol level 
   You have a close blood relative who had a heart attack or 
   heart surgery before age 55 (father or brother) or age 65 
       (mother or sister) 
   You are physically inactive (i.e. you get < 30 minutes of  
If you marked any of these 
statements in this section, consult 
your physician or other appropriate 
health care provider before engaging 
in exercise.  You may need to use a 
facility with a medically qualified 
staff. 
If you marked two or more of the 
statements in this section, you 
should consult your physician or 
other appropriate health care 
provider before engaging in 
exercise.  You might benefit from 
using a facility with a 
professionally qualified exercise 





   physical activity on at least 3 days of the week) 
   You are > 20 pounds overweight 
 
 
   None of the above 
 
 
You should be able to exercise safely 
without consulting your physician or 
other appropriate health care 
provider in a self-guided program or 
almost any facility that meets your 






24-HOUR DIET RECORD 
 
Subject number____________  Date______________Day of Week______________ 
 
  Adapted From:  Lee RD, Nieman DC. Nutritional Assessment. 2nd ed. United States of America: Mosby; 1996.






     
     
     
     
     
     
     
     
     






40-Day Physical Activity Records 
 
Subject #    Trial #    Date:   
 
Date 






(use scale below) 
    
 
    
 
    
 
    
 
    
 
    
 
    
 
    
 
    
 
    
 
    
 
    
 
    
 

















7 Very, very light 
8 
9 Very light 
10 
11 Fairly light 
12 




17 Very hard 
18 




































Subject Prescreening Information 
 




Height       Weight                 Blood Pressure _______________ 
 
Typical Exercise Habits over the Past 3 Months: 
 
Average number of days of exercise per week     
 
Average number of hours of exercise per week    
 
Type of Exercise_______________________ 
 
 
Do you have a muscle or joint injury/condition that precludes the completion of 
the strenuous unilateral leg extension protocol? If yes, please explain. 
 
 
Are you allergic to Aspirin or any Non-Steroidal Anti-Inflammatory Drugs 
(NSAIDs) such as Ibuprofen, Motrin, Advil, etc.,?  Have you taken any within 
the past 7 days? 
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